FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149282675> ?p ?o ?g. }

• W2149282675 abstract "A key phenomenon in rheumatoid arthritis is the formation of lymphoid follicles in the inflamed synovial membrane. C-X-C motif chemokine 13 (CXCL13) is central in this process as it attracts C-X-C chemokine receptor type 5 (CXCR5)-expressing B cells and T follicular helper cells to the follicle. We here examine the role of CXCL13 and its association with disease in patients with treatment-naïve early rheumatoid arthritis. Plasma samples from patients in the OPERA trial were examined for CXCL13 at treatment initiation and after 6 months of treatment with either methotrexate plus placebo (DMARD) (n = 37) or methotrexate plus adalimumab (DMARD + ADA) (n = 39). Treatment outcome was evaluated after 1 and 2 years. CXCL13 plasma levels in healthy volunteers (n = 38) were also examined. Baseline CXCL13 plasma levels were increased in early rheumatoid arthritis patients in comparison with healthy volunteers. Also, plasma CXCL13 correlated positively with disease activity parameters; swollen joint count 28 (rho = 0.34) and 40 (rho = 0.39), visual analog score (rho = 0.38) and simplified disease activity index (rho = 0.25) (all P <0.05). CXCL13 levels decreased a significantly twofold more in the DMARD + ADA group than in the DMARD group. Baseline CXCL13 plasma levels in the DMARD group correlated inversely with disease activity parameters; disease activity score in 28 joints, four variables, C-reactive protein based (DAS28CRP) (rho = 0.58, P <0.05) at 12 months. High baseline CXCL13 was associated with remission (DAS28CRP less than 2.6) after 2 years. In treatment-naïve early rheumatoid arthritis patients, plasma CXCL13 levels were associated with joint inflammation. Furthermore, patients with high baseline plasma CXCL13 levels had an improved chance of remission after 2 years. We propose that high CXCL13 concentrations indicate recent onset of inflammation that may respond better to early aggressive treatment. Thus, high levels of CXCL13 could reflect the `the window of opportunity' for optimal treatment effect. Clinicaltrial.gov NCT00660647 . Registered 10 April 2008" @default.
• W2149282675 created "2016-06-24" @default.
• W2149282675 creator A5010602035 @default.
• W2149282675 creator A5021102169 @default.
• W2149282675 creator A5027580621 @default.
• W2149282675 creator A5029636602 @default.
• W2149282675 creator A5042428908 @default.
• W2149282675 creator A5050897744 @default.
• W2149282675 creator A5056189838 @default.
• W2149282675 creator A5063586848 @default.
• W2149282675 creator A5071248640 @default.
• W2149282675 creator A5072664936 @default.
• W2149282675 creator A5082115106 @default.
• W2149282675 date "2014-09-24" @default.
• W2149282675 modified "2023-10-17" @default.
• W2149282675 title "CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic `window of opportunity'" @default.
• W2149282675 cites W1557965753 @default.
• W2149282675 cites W1589732879 @default.
• W2149282675 cites W1612160402 @default.
• W2149282675 cites W1824520085 @default.
• W2149282675 cites W1979256019 @default.
• W2149282675 cites W1992988295 @default.
• W2149282675 cites W2022039920 @default.
• W2149282675 cites W2042802562 @default.
• W2149282675 cites W2059241638 @default.
• W2149282675 cites W2088104857 @default.
• W2149282675 cites W2094298864 @default.
• W2149282675 cites W2098134859 @default.
• W2149282675 cites W2100233061 @default.
• W2149282675 cites W2100314147 @default.
• W2149282675 cites W2112753756 @default.
• W2149282675 cites W2139625651 @default.
• W2149282675 cites W2156996668 @default.
• W2149282675 cites W2168125040 @default.
• W2149282675 cites W2170040488 @default.
• W2149282675 doi "https://doi.org/10.1186/s13075-014-0434-z" @default.
• W2149282675 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4201737" @default.
• W2149282675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25249397" @default.
• W2149282675 hasPublicationYear "2014" @default.
• W2149282675 type Work @default.
• W2149282675 sameAs 2149282675 @default.
• W2149282675 citedByCount "60" @default.
• W2149282675 countsByYear W21492826752015 @default.
• W2149282675 countsByYear W21492826752016 @default.
• W2149282675 countsByYear W21492826752017 @default.
• W2149282675 countsByYear W21492826752018 @default.
• W2149282675 countsByYear W21492826752019 @default.
• W2149282675 countsByYear W21492826752020 @default.
• W2149282675 countsByYear W21492826752021 @default.
• W2149282675 countsByYear W21492826752022 @default.
• W2149282675 countsByYear W21492826752023 @default.
• W2149282675 crossrefType "journal-article" @default.
• W2149282675 hasAuthorship W2149282675A5010602035 @default.
• W2149282675 hasAuthorship W2149282675A5021102169 @default.
• W2149282675 hasAuthorship W2149282675A5027580621 @default.
• W2149282675 hasAuthorship W2149282675A5029636602 @default.
• W2149282675 hasAuthorship W2149282675A5042428908 @default.
• W2149282675 hasAuthorship W2149282675A5050897744 @default.
• W2149282675 hasAuthorship W2149282675A5056189838 @default.
• W2149282675 hasAuthorship W2149282675A5063586848 @default.
• W2149282675 hasAuthorship W2149282675A5071248640 @default.
• W2149282675 hasAuthorship W2149282675A5072664936 @default.
• W2149282675 hasAuthorship W2149282675A5082115106 @default.
• W2149282675 hasBestOaLocation W21492826751 @default.
• W2149282675 hasConcept C126322002 @default.
• W2149282675 hasConcept C12823836 @default.
• W2149282675 hasConcept C13373296 @default.
• W2149282675 hasConcept C198451711 @default.
• W2149282675 hasConcept C203014093 @default.
• W2149282675 hasConcept C2776708503 @default.
• W2149282675 hasConcept C2776914184 @default.
• W2149282675 hasConcept C2777138892 @default.
• W2149282675 hasConcept C2777575956 @default.
• W2149282675 hasConcept C2779134260 @default.
• W2149282675 hasConcept C2780132546 @default.
• W2149282675 hasConcept C71924100 @default.
• W2149282675 hasConcept C75877943 @default.
• W2149282675 hasConcept C90924648 @default.
• W2149282675 hasConceptScore W2149282675C126322002 @default.
• W2149282675 hasConceptScore W2149282675C12823836 @default.
• W2149282675 hasConceptScore W2149282675C13373296 @default.
• W2149282675 hasConceptScore W2149282675C198451711 @default.
• W2149282675 hasConceptScore W2149282675C203014093 @default.
• W2149282675 hasConceptScore W2149282675C2776708503 @default.
• W2149282675 hasConceptScore W2149282675C2776914184 @default.
• W2149282675 hasConceptScore W2149282675C2777138892 @default.
• W2149282675 hasConceptScore W2149282675C2777575956 @default.
• W2149282675 hasConceptScore W2149282675C2779134260 @default.
• W2149282675 hasConceptScore W2149282675C2780132546 @default.
• W2149282675 hasConceptScore W2149282675C71924100 @default.
• W2149282675 hasConceptScore W2149282675C75877943 @default.
• W2149282675 hasConceptScore W2149282675C90924648 @default.
• W2149282675 hasIssue "5" @default.
• W2149282675 hasLocation W21492826751 @default.
• W2149282675 hasLocation W21492826752 @default.
• W2149282675 hasLocation W21492826753 @default.
• W2149282675 hasLocation W21492826754 @default.
• W2149282675 hasOpenAccess W2149282675 @default.
• W2149282675 hasPrimaryLocation W21492826751 @default.
• W2149282675 hasRelatedWork W1555548379 @default.

• next